Full Generic Medicine Info
Dosage/Direction for Use

Adult: As macrogol 4000 powd: 10-20 g once daily. As macrogol 3350 powd: Initially, 17 g once daily, may be increased to bid depending on the response. Max treatment duration: 1 wk.
Child: As macrogol 4000 powd: ≥8 yr Initially, 10 g every other day, may be increased up to 20 g once daily. Max treatment duration: 3 mth. As macrogol 3350 powd: 4-5 yr Initially, 8.5 g once daily, may be increased up to a max of 17 g once daily according to response. 6-12 yr 17 g once daily. May be increased or decreased according to response. Max: 25.5 g daily. ≥12 yr Same as adult dose. Max treatment duration: 3 mth.
GI disorders (e.g. ileus, intestinal obstruction, ulcerative colitis, toxic megacolon, Crohn's disease, digestive perforation, painful abdominal syndrome).
Special Precautions
Patient w/ CV disease e.g. CHF, ascitic conditions. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Assess for symptoms of bowel obstruction prior to treatment.
Adverse Reactions
Significant: Fluid and electrolyte imbalance, hypersensitivity reactions (e.g rash, urticaria, oedema). GI: Nausea, vomiting, diarrhoea, anal irritation, bloating, abdominal distention, cramps, pain, urgency to defecate, fecal incontinence.
Symptoms: Diarrhoea, vomiting, abdominal pain, fluid and electrolyte imbalance. Management: Supportive therapy to correct fluid and electrolyte disturbance.
Macrogols or polyethylene glycol (PEG) are long linear polymers w/ osmotic activity. It binds water molecules and retains water in the stool, thus increasing the vol of intestinal fluids causing laxative effect.
Onset: W/in 1 hr.
Absorption: Poorly absorbed from the GI tract.
Excretion: Mainly via faeces (93%); urine (0.2%).
Oral: Store between 20-25°C.
CIMS Class
Laxatives, Purgatives
ATC Classification
A06AD15 - macrogol ; Belongs to the class of osmotically acting laxatives.
Disclaimer: This information is independently developed by CIMS based on macrogol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in